Prulifloxacin
Authors:
- 1 January 2004
- journal article
- clinical trial
- Published by Springer Nature in Drugs
- Vol. 64 (19) , 2221-2234
Abstract
▲ Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. After absorption, prulifloxacin is metabolised by esterases to ulifloxacin. The drug has a long elimination half-life, allowing once-daily administration. ▲ Ulifloxacin is generally more active in vitro than other fluoroquinolones against a variety of clinical isolates of Gram-negative bacteria, including community and nosocomial isolates of Escherichia coli, Klebsiella spp., Proteus, Providencia and Morganella spp., Moraxella catarrhalis and Haemophilus spp. The activity of ulifloxacin against Pseudomonas aeruginosa varies between countries. ▲ Gram-positive organisms, including meticillin- or oxacillin-susceptible Staphylococcus aureus, Enterococcus spp. and Italian community isolates of Streptococcus pneumoniae are susceptible to ulifloxacin. Activity against Spanish strains of S. pneumoniae is moderate. ▲ In well designed clinical trials, good clinical and bacteriological efficacy (similar to that of ciprofloxacin, amoxicillin/clavulanic acid or pefloxacin) was seen with prulifloxacin 600mg once daily for 10 days in patients with acute exacerbations of chronic bronchitis or complicated lower urinary tract infections (UTIs), and with single-dose prulifloxacin 600mg in acute, uncomplicated lower UTIs. ▲ Prulifloxacin was generally well tolerated in clinical trials, with a similar tolerability profile to that of ciprofloxacin.Keywords
This publication has 26 references indexed in Scilit:
- Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent AdultsClinical Infectious Diseases, 2003
- Pharmacokinetics and Tolerability of Prulifloxacin after Single Oral AdministrationArzneimittelforschung, 2003
- In Vitro Activity of the Active Metabolite of Prulifloxacin (AF 3013) Compared with Six Other FluoroquinolonesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- In Vitro Antibacterial Activities of AF 3013, the Active Metabolite of Prulifloxacin, against Nosocomial and Community Italian IsolatesAntimicrobial Agents and Chemotherapy, 2001
- EAU Guidelines for the Management of Urinary and Male Genital Tract Infections1European Urology, 2001
- Complicated urinary tract infectionsInternational Journal of Antimicrobial Agents, 2000
- Guidelines for Antimicrobial Treatment of Uncomplicated Acute Bacterial Cystitis and Acute Pyelonephritis in WomenClinical Infectious Diseases, 1999
- CiprofloxacinDrugs, 1996
- Antibacterial activity of NM394, the active form of prodrug NM441, a new quinoloneAntimicrobial Agents and Chemotherapy, 1993
- In vivo evaluation of NM441, a new thiazeto-quinoline derivativeAntimicrobial Agents and Chemotherapy, 1991